The development of reliable biomarkers is critical for early PD diagnosis (193), patient selection for the enrolment to clinical trials, to identify patients in which LRRK2 inhibition may be most effective and allow for personalized dose adjustments (196). This evidence concerns the gene LRRK2 and Parkinson disease.